Background: Mortality related to complications of cirrhosis is increasing in patients with insulin-resistance factors. Hyperlipidaemic patients have multiple risk factors of insulin resistance. It is impossible to perform liver biopsy in such a large number of hyperlipidaemic patients to identify patients with advanced liver fibrosis or with steatohepatitis (non-alcoholic steatohepatitis, NASH).
Aims: To use the non-invasive biomarkers, FibroTest (FT), SteatoTest and NashTest, and to assess the prevalence of advanced liver disease in a large population of hyperlipidaemic patients.
Methods: A consecutive cohort of hyperlipidaemic patients was followed prospectively in a lipid centre and the sera were analysed retrospectively.
Results: A total of 2834 subjects were included: 1909 hyperlipidaemic patients and 925 blood donors (BD). Advanced fibrosis was identified by FT in 53/1909 (2.8%) hyperlipidaemic patients vs. 0/925 BD (0%) (P < 0.0001); advanced steatosis in 569/1893 hyperlipidaemic patients (30.1%) vs. 8/164 (4.9%) BD (P < 0.0001) and NASH in 132/1893 (7%) vs. 0/164 (0%), respectively (P < 0.0001). There was a highly significant and linear association between the number of metabolic syndrome factors and liver disease prevalence - the highest being for type 2 diabetics: advanced steatosis 66%, NASH 24% and advanced fibrosis 6%. CONCLUSIONS The prevalence of fibrosis, steatosis and NASH in hyperlipidaemic patients appears to be high (3%, 30% and 7%, respectively). Biomarkers could be useful for screening of advanced fibrosis and NASH in patients with several metabolic syndrome factors, to prevent liver mortality.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1365-2036.2006.03182.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparison of Friedewald, Martin/Hopkins, and Sampson formulae with direct LDL measurement in hyperlipidaemic and normolipidaemic adults in a Turkish population.
J Med Biochem
September 2024
University of Health Sciences, Ankara Training and Research Hospital, Medical Biochemistry, Ankara, Türkiye.
Methods: The study was a retrospective investigation by the Department of Medical Biochemistry of the Ankara Training and Research Hospital between January 1, 2021, and December 31, 2022. Our study evaluated the results of 6297 patients aged 18-95 years who underwent cholesterol panel TC, TG, HDL-C, and direct LDL-C in our laboratory. The estimated LDL-C was calculated according to Friedewald, Martin/Hopkins, and Sampson formulae.
View Article and Find Full Text PDFLipoprotein(a) distribution in hospitalised Asian patients with ischaemic heart disease.
Ther Adv Cardiovasc Dis
December 2024
Department of Cardiology, Changi General Hospital, Singapore, Singapore.
Background: Elevated lipoprotein(a) [Lp(a)] is a common hyperlipidaemic condition with strong genetic predisposition and is independently associated with ischaemic heart disease (IHD). A Mendelian randomisation study has suggested that elevated Lp(a) is likely to confer similar causal risks as heterozygous familial hypercholesterolemia for premature IHD. We aimed to characterise the clinical profiles of admitted patients with IHD with at least one Lp(a) measurement.
View Article and Find Full Text PDFEffects of Hawthorn Fruit Extract Drink in Chinese Patients With Mild Hypertension and/or Hyperlipidaemia: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study.
Dose Response
November 2024
Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China.
Article Synopsis
- * 61 participants consumed either the hawthorn drink or placebo over 8 weeks, and metrics like blood pressure, lipid profiles, and glucose levels were recorded, noting no significant differences between the two groups.
- * Results suggested a minimal trend towards fewer adverse effects with hawthorn, but overall findings did not indicate significant benefits, prompting a recommendation for longer studies with controlled calorie intake.
Phospholipid and glycerolipid metabolism as potential diagnostic biomarkers for acute pancreatitis.
Lipids Health Dis
July 2024
Clinical Center for Molecular Diagnosis and Therapy, the Second Affiliated Hospital of Fujian Medical University, Quanzhou, 362000, Fujian, China.
Background: Acute pancreatitis (AP) is characterized as a systemic inflammatory condition posing challenges in diagnosis and prognosis assessment. Lipid metabolism abnormalities, especially triacylglycerol (TAG) levels, have been reported, indicating their potential as biomarkers in acute pancreatitis. However, the performance of the TAG cycle, including phospholipid and glycerolipid metabolism, in AP patients has not yet been reported.
View Article and Find Full Text PDFMicrobiota based personalized nutrition improves hyperglycaemia and hypertension parameters and reduces inflammation: a prospective, open label, controlled, randomized, comparative, proof of concept study.
PeerJ
July 2024
Leucine Rich Bio Pvt Ltd, Bengaluru, India.
Article Synopsis
- Recent research indicates that the gut microbiota plays a crucial role in chronic diseases like type 2 diabetes, and personalized nutrition based on microbiome profiles could offer health benefits.
- In a clinical trial involving 30 participants with type 2 diabetes and hyperlipidaemia, one group received nutrition tailored to their microbiome, while the other received standard diabetic guidance.
- Results showed significant health improvements in the personalized nutrition group, including a drop in HbA1c levels, reduced systolic blood pressure, and decreased C-reactive protein levels over 90 days.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!